H. Relas

发表

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration

L. Jacobsson, M. Santos, Gareth T. Jones, 2021, Annals of the Rheumatic Diseases.

Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins.

H. Gylling, T. Miettinen, T. Miettinen, 2003, The Journal of laboratory and clinical medicine.

Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review

L. Pirilä, I. Kohonen, R. Huovinen, 2020, Rheumatology advances in practice.

Effect of stanol ester on postabsorptive squalene and retinyl palmitate.

H. Gylling, T. Miettinen, H. Relas, 2000, Metabolism: clinical and experimental.

Postprandial retinyl palmitate and squalene metabolism is age dependent.

H. Gylling, T. Miettinen, R. Rajaratnam, 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

Delayed postprandial retinyl palmitate and squalene removal in a patient heterozygous for apolipoprotein A-IFIN mutation (Leu 159-->Arg) and low HDL cholesterol level without coronary artery disease.

H. Gylling, T. Miettinen, H. Miettinen, 1996, Atherosclerosis.

Adalimumab and sulfasalazine in alleviating sacroiliac and aortic inflammation detected in PET/CT in patients with axial spondyloarthritis: PETSPA

T. Nieminen, T. Kerola, M. Kauppi, 2021, Immunity, inflammation and disease.

Fate of intravenously administered squalene and plant sterols in human subjects.

H. Gylling, T. Miettinen, H. Relas, 2001, Journal of lipid research.

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.

K. Pavelka, D. D. Giuseppe, M. Santos, 2022, Seminars in arthritis and rheumatism.

Outcomes of switching anti-TNF drugs in rheumatoid arthritis—a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN)

Y. Konttinen, D. Nordström, S. Sihvonen, 2011, Clinical Rheumatology.

Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries

C. Turesson, J. Askling, B. Delcoigne, 2022, Annals of the Rheumatic Diseases.

Acute effect of dietary stanyl ester dose on post-absorptive α-tocopherol, β-carotene, retinol and retinyl palmitate concentrations

H. Gylling, T. Miettinen, H. Relas, 2001 .

Postprandial vitamin A and squalene clearances and cholesterol synthesis off and on lovastatin treatment in type III hyperlipoproteinemia.

H. Gylling, T. Miettinen, H. Relas, 1995, Atherosclerosis.

Dietary squalene increases cholesterol synthesis measured with serum non-cholesterol sterols after a single oral dose in humans.

H. Gylling, T. Miettinen, H. Relas, 2000, Atherosclerosis.

Rates of Serious Infections and Malignancies Among Patients with Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy

Y. Konttinen, T. Sokka, D. Nordström, 2015, The Journal of Rheumatology.

Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis

T. Jokiranta, J. Rutanen, M. Leirisalo-Repo, 2021, Rheumatology International.

OP0109 CO-MEDICATION WITH A CONVENTIONAL SYNTHETIC DMARD IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IS ASSOCIATED WITH IMPROVED RETENTION OF TNF INHIBITORS: RESULTS FROM THE EUROSPA COLLABORATION

L. Jacobsson, H. Mann, G. Macfarlane, 2020, Annals of the Rheumatic Diseases.

METABOLISM OF SQUALENE IN TRIGLYCERIDE-RICH LIPOPROTEINS IN HUMANS

H. Relas, H. Relas, 2001 .

Use of Synthetic and Biological DMARDs in Treatment of Ankylosing Spondylitis at a University Hospital

H. Kautiainen, M. Leirisalo-Repo, K. Puolakka, 2014 .

Survival of disease-modifying antirheumatic drugs used as the first antirheumatic medication in the treatment of ankylosing spondylitis in Finland. A nationwide population-based register study

L. Virta, H. Kautiainen, M. Leirisalo-Repo, 2014, Clinical Rheumatology.

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis

J. Rutanen, D. Nordström, K. Aaltonen, 2019, PloS one.

G-CSF- AND CHEMOTHERAPY-INDUCED LARGE-VESSEL VASCULITIS — SIX PATIENT CASES AND A SYSTEMATIC LITERATURE REVIEW

L. Pirilä, I. Kohonen, K. Taimen, 2020 .

Impact of TNF inhibitor medication on working ability in axial spondyloarthritis: an observational national registry-based cohort study

J. Rutanen, D. Nordström, K. Aaltonen, 2023, Rheumatology advances in practice.

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis.

L. Jacobsson, H. Mann, M. Santos, 2022, Rheumatology.

One-third of European axial spondyloarthritis patients reach pain"remission" with routine care TNF-inhibitor treatment.

G. Jones, G. Macfarlane, K. Pavelka, 2022, Journal of Rheumatology.

The feasibility of existing JADAS10 cut-off values in clinical practice: a study of data from The Finnish Rheumatology Quality Register

K. Aalto, E. Löyttyniemi, L. Kuusalo, 2023, Pediatric Rheumatology Online Journal.

Pain interference and associated factors in young adults with juvenile idiopathic arthritis

H. Kautiainen, K. Aalto, T. Orenius, 2019, Scandinavian journal of rheumatology.

Patients with psychiatric diagnoses have lower quality of life than other patients with juvenile rheumatic disease: a prospective study

S. Kosola, H. Relas, 2021, Rheumatology.

Disability and health-related quality of life are associated with restricted social participation in young adults with juvenile idiopathic arthritis

H. Kautiainen, K. Aalto, T. Orenius, 2018, Scandinavian journal of rheumatology.

Acceptable quality of life and low disease activity achievable among transition phase patients with rheumatic disease

S. Kosola, H. Relas, 2018, Clinical Rheumatology.

Outcome of transition phase patients with juvenile idiopathic arthritis

S. Kosola, R. Luosujärvi, H. Relas, 2018, Modern rheumatology.

Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers

J. Askling, K. Hellgren, B. Delcoigne, 2023, RMD Open.

S. Kosola, P. Miettinen, K. Kolho, 2024, BMC pediatrics.

Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

B. Gudbjornsson, T. Love, F. Iannone, 2024, The Journal of Rheumatology.

Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response

B. Glintborg, Ž. Rotar, H. Relas, 2024, Scandinavian journal of rheumatology.